|
| Press Releases |
|
 |
|
| Wednesday, April 9, 2025 |
|
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
| SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
|
中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果 |
| 中國抗體製藥有限公司（「中國抗體」或「本公司」；股份代號：3681）宣佈，其SM17針對中重度特應性皮炎（AD）的創新療法已完成1b期臨床研究，並獲得突破性頂線數據結果。 more info >> |
|
|
中国抗体制药有限公司SM17治疗特应性皮炎1b期概念验证临床试验取得突破性结果 |
| 中国抗体制药有限公司（“中国抗体”或“本公司”；股份代号：3681）宣布，其SM17针对中重度特应性皮炎（AD）的创新疗法已完成1b期临床研究，并获得突破性顶线数据结果。 more info >> |
|
| Tuesday, April 16, 2024 |
|
|
中国抗体SM17治疗特应性皮炎（AD）之临床前结果刊登于国际科学期刊《Allergy》 |
| more info >> |
|
|
中國抗體SM17治療特應性皮炎（AD）之臨床前結果刊登於國際科學期刊《Allergy》 |
| more info >> |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
中国抗体SM17新药研究申请再获国家药监局批准 |
| 专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司（上市编号：3681.HK，下称“中国抗体”或“本公司”）欣然宣布，本公司所提交之治疗特应性皮炎（“AD”）的同类首创（First-in-Class）治疗产品SM17的新药研究申请（“新药研究申请”） more info >> |
|
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
| 專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司（上市編號：3681.HK，下稱「中國抗體」或「本公司」）欣然宣佈，本公司所提交之治療特應性皮炎（「AD」）的同類首創（First-in-Class）治療產品SM17的新藥研究申請（「新藥研究申請」） more info >> |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
| 专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司（上市编号：3681.HK，下称“中国抗体”或“本公司”）欣然宣布，本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请（“新药研究申请”）于2023年8月11日获中国国家药品监督管理局（“国家药监局”）批准。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Japantastics Launches Global Curator Platform Bringing Japan Craftsmanship to the World
Feb 4, 2026 22:00 JST
|
|
|
The 55-Point Gap: Measuring What Matters in Automotive Impact
Feb 4, 2026 18:00 JST
|
|
|
Mitsubishi Heavy Industries Announces Large Order Intake, Revenue, and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 4, 2026 17:13 JST
|
|
|
Airwheel Introduces AI-Driven Rideable Smart Cabin Suitcase Solutions for the Next Generation of Global Travel
Feb 4, 2026 15:00: JST
|
|
|
Airwheel Introduces AI-Driven Rideable Smart Cabin Suitcase Solutions for the Next Generation of Global Travel
Feb 4, 2026 14:00 HKT/SGT
|
|
|
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 4, 2026 13:30 JST
|
|
|
華泰經紀攜手菲律賓Aboitiz Power集團 臨港首啟2026全球統保路演 賦能共建「一帶一路」能源合作
Feb 4, 2026 12:26 HKT/SGT
|
|
|
Honda Co-developing Automobile SoC with U.S.-based Mythic to Accelerate Research to Enhance AI Computing Performance and Energy Efficiency
Feb 4, 2026 11:32 JST
|
|
|
東方大鵬今日始：解碼「功能飲料第一股」東鵬飲料的長期價值底色
Feb 4, 2026 10:04 HKT/SGT
|
|
|
东方大鹏今日始：解码"功能饮料第一股"东鹏饮料的长期价值底色
Feb 4, 2026 10:04 HKT/SGT
|
|
|
Casa Minerals Inc. Announces Closing of First Tranche of Private Placement
Feb 4, 2026 07:59 HKT/SGT
|
|
|
先導智能赴港招股：新能源裝備龍頭 開啟全球增長新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
先导智能赴港招股：新能源装备龙头 开启全球增长新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
卡奧斯遞表港交所：工業數智化龍頭 為製造業培育新質生產力注入強勁動能
Feb 3, 2026 19:20 HKT/SGT
|
|
|
DENSO Announces Third Quarter Financial Results
Feb 3, 2026 19:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
